AddaS03™| AS03- like adjuvant | InvivoGen
State Purchased Flu Vaccine Storage and Handling Incident Reporting Process
Sanofi and GSK receive up to $2.1B from the U.S. to deliver COVID-19 vaccine | 2020-07-31 | BioWorld
GSk Vaccine Manufcaturing Plant, St Amand Les Eaux - Pharmaceutical Technology
Vaccines partnering to give your science and technology a global impact
Pharmacy Resources | GSKPro for Healthcare Professionals
Clover nears pivotal trial of GSK-adjuvanted COVID-19 vaccine | Fierce Biotech
Serum's heat-stable rotavirus vaccine shines in phase 3 | Fierce Pharma
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development | ACS Central Science
Partnering with GSK to accelerate vaccine R&D
Disease Education | Vaccines | GSK US Medical Affairs
GSK invests further in vaccines with $190m buy of GlycoVaxyn
COVID-19 mRNA vaccines: Platforms and current developments: Molecular Therapy
Vaccine Stability Calculator | GSK US Medical Affairs
Vaccines | Free Full-Text | CMC Strategies and Advanced Technologies for Vaccine Development to Boost Acceleration and Pandemic Preparedness
Vaccine Stability Calculator | GSK US Medical Affairs
Vaccines | Free Full-Text | Use of Stability Modeling to Support Accelerated Vaccine Development and Supply
Vaccine Stability Calculator | GSK US Medical Affairs
Can Sanofi And GSK Catch Up In mRNA Vaccines? :: Scrip
GSK vaccine chief aims to break dominance of mRNA shots | Financial Times
Coding Support and Resources | GSKPro for Healthcare Professionals
GSK Vaccines Packaging | GSKPro for Healthcare Professionals
CureVac and GSK announce promising preclinical data for next-gen COVID-19 vaccine - Drug Discovery and Development
Cervarix™, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions: Human Vaccines: Vol 5, No 7
Statement on Rotarix® and Vaccine Vial Monitor (VVM) compliance Rotarix® is produced by GlaxoSmithKline Biologicals SA (here b
